My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

15.02 -0.13 (-0.86%)

Streaming Delayed Price Updated: 11:19 AM EST, Jan 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2 3 4 5 6 7 Next >

Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗

December 02, 2025

A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next.

Via The Motley Fool

AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) Passes Louis Navellier's Strict Growth Stock Screen ↗

November 07, 2025

Aurinia Pharmaceuticals (AUPH) exemplifies a top growth stock, showing explosive earnings growth, soaring cash flow, and consistent earnings surprises.

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

A Peek at Aurinia Pharmaceuticals's Future Earnings ↗

November 03, 2025

Via Benzinga

FDA Drug Chief George Tidmarsh Resigns After Allegations Of Power Misuse ↗

November 03, 2025

FDA drug center head George Tidmarsh resigned after accusations of misusing power to harm a former business associate. He denies wrongdoing.

Via Benzinga

Aurinia Pharma Stands By Lupus Drug After FDA Official’s Retracted Post Sparks 16% Selloff — Retail Stays Bullish On Recovery ↗

September 29, 2025

Via Stocktwits

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

Earnings Scheduled For May 12, 2025 ↗

May 12, 2025

Via Benzinga

FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’ ↗

November 02, 2025

Things got murkier at the FDA’s drug evaluation agency as its acting director stepped down, alleging that a new drug approval program injected politics, superseding decisions based on science.

Via Stocktwits

Topics Lawsuit

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Traits in Fundamental Analysis ↗

October 17, 2025

Discover Aurinia Pharmaceuticals (AUPH), a top growth stock with explosive earnings, soaring revenue, and high ROE, using Louis Navellier's proven investment strategy.

Via Chartmill

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 29, 2025

Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's market cap stands at $2.2 million.

Via Benzinga

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Passes Louis Navellier's Growth Screen ↗

September 26, 2025

Aurinia Pharmaceuticals (AUPH) is a top growth stock pick based on Louis Navellier's strategy, showing explosive earnings growth, strong sales momentum, and rising profit margins.

Via Chartmill

United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results ↗

September 10, 2025

United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one.

Via Investor's Business Daily

Topics ETFs

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Metrics and Earnings Momentum ↗

September 05, 2025

Aurinia Pharma (AUPH) shows strong growth momentum with surging earnings, impressive sales growth, and major margin expansion, making it a top pick for growth investors.

Via Chartmill

Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded ↗

August 26, 2025

Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday.

Via Investor's Business Daily

Topics ETFs

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Fits Louis Navellier’s High-Growth Stock Criteria ↗

August 15, 2025

Louis Navellier's growth strategy highlights Aurinia Pharmaceuticals (AUPH) for strong earnings momentum, rising revenue, and solid ROE—key traits for high-growth stock success.

Via Chartmill

Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter? ↗

August 04, 2025

The upgraded score means Gilead is now outperforming 96% of all stocks in terms of the most important stock-picking criteria.

Via Investor's Business Daily

Aurinia (AUPH) Q2 Revenue Jumps 22% ↗

July 31, 2025

Via The Motley Fool

Topics Intellectual Property

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors ↗

July 24, 2025

Aurinia Pharmaceuticals (AUPH) meets key growth criteria from Louis Navellier’s strategy, with strong earnings, sales growth, and improving margins. The stock shows solid financial health and...

Via Chartmill

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors ↗

July 01, 2025

Aurinia Pharmaceuticals (NASDAQ:AUPH) shows strong growth metrics, including surging earnings, revenue, and cash flow, making it a candidate for investors following Louis Navellier’s strategy.

Via Chartmill

Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results ↗

June 30, 2025

AUR200 targets both BAFF and APRIL, which are key immune system proteins. It is being developed for one large indication and one rare disease.

Via Stocktwits

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors ↗

June 10, 2025

Aurinia Pharmaceuticals (AUPH) shows strong growth, earnings momentum, and improving margins, making it a candidate for investors following Louis Navellier’s strategy.

Via Chartmill

US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert ↗

May 23, 2025

U.S. stock futures were fluctuating on Friday after a mixed close on Thursday. Futures of benchmark indices were mixed in premarket.

Via Benzinga

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors ↗

May 19, 2025

Aurinia Pharmaceuticals (AUPH) meets Louis Navellier’s growth criteria with strong earnings surprises, accelerating revenue, and improving margins. A solid pick for growth-focused investors.

Via Chartmill

Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance ↗

May 12, 2025

Aurinia posts Q1 profit and 25% LUPKYNIS sales growth, reports $62.47 million revenue, and reaffirms full-year guidance.

Via Benzinga

Aurinia Stock Rallies On Upbeat Q1 Earnings, CEO Expects Strong Performance in 2025: Retail Sentiment Brightens ↗

May 12, 2025

The company also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.

Via Stocktwits

Uncovering Potential: Aurinia Pharmaceuticals's Earnings Preview ↗

May 09, 2025

Via Benzinga

Is AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) following the Minervini trend for explosive growth? ↗

March 29, 2025

Should you consider AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) for high growth investing? A fundamental and technical analysis of (NASDAQ:AUPH).

Via Chartmill

Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet ↗

March 07, 2025

Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%.

Via Stocktwits

Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations ↗

February 27, 2025

Aurinia Pharmaceuticals reported Q4 earnings of 1 cent per share, beating estimates, with LUPKYNIS sales up 36%.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.